Apple Appealing against UK 'Back Door' Order, Tribunal Confirms

Apple iPhone 16 smartphones are displayed at a store in London, Britain, October 6, 2024. REUTERS/Hollie Adams/File Photo
Apple iPhone 16 smartphones are displayed at a store in London, Britain, October 6, 2024. REUTERS/Hollie Adams/File Photo
TT
20

Apple Appealing against UK 'Back Door' Order, Tribunal Confirms

Apple iPhone 16 smartphones are displayed at a store in London, Britain, October 6, 2024. REUTERS/Hollie Adams/File Photo
Apple iPhone 16 smartphones are displayed at a store in London, Britain, October 6, 2024. REUTERS/Hollie Adams/File Photo

Apple is appealing against a British government order to create a "back door" to its encrypted cloud storage systems, the Investigatory Powers Tribunal (IPT) confirmed on Monday.

The IPT said in a written judgment that it had refused an application by the British government that "the bare details of the case", including that it was brought by Apple, be kept private.

The ruling follows a hearing in London last month, which was held in secret with media not allowed to attend.

The Washington Post reported in February that Britain had issued a "technical capability notice" to Apple to enable access to encrypted messages and photos, even for users outside the country, Reuters reported.

The iPhone maker in response removed its most advanced security encryption for cloud data, called Advanced Data Protection, for new users in Britain.

Details of the case have been shrouded in

secrecy

and neither Apple nor the British government have publicly confirmed the technical capability notice.



AI Tool Uses Selfies to Predict Biological Age and Cancer Survival

Three pedestrians take a selfie on the picturesque alleyway at the end of Rue de l'Universite, Paris. Ian LANGSDON / AFP/File
Three pedestrians take a selfie on the picturesque alleyway at the end of Rue de l'Universite, Paris. Ian LANGSDON / AFP/File
TT
20

AI Tool Uses Selfies to Predict Biological Age and Cancer Survival

Three pedestrians take a selfie on the picturesque alleyway at the end of Rue de l'Universite, Paris. Ian LANGSDON / AFP/File
Three pedestrians take a selfie on the picturesque alleyway at the end of Rue de l'Universite, Paris. Ian LANGSDON / AFP/File

Doctors often start exams with the so-called "eyeball test" -- a snap judgment about whether the patient appears older or younger than their age, which can influence key medical decisions.

That intuitive assessment may soon get an AI upgrade.

FaceAge, a deep learning algorithm described Thursday in The  Lancet Digital Health, converts a simple headshot into a number that more accurately reflects a person's biological age rather than the birthday on their chart.

Trained on tens of thousands of photographs, it pegged cancer patients on average as biologically five years older than healthy peers. The study's authors say it could help doctors decide who can safely tolerate punishing treatments, and who might fare better with a gentler approach.

"We hypothesize that FaceAge could be used as a biomarker in cancer care to quantify a patient's biological age and help a doctor make these tough decisions," said co-senior author Raymond Mak, an oncologist at Mass Brigham Health, a Harvard-affiliated health system in Boston.

Consider two hypothetical patients: a spry 75‑year‑old whose biological age clocks in at 65, and a frail 60‑year‑old whose biology reads 70. Aggressive radiation might be appropriate for the former but risky for the latter.

The same logic could help guide decisions about heart surgery, hip replacements or end-of-life care.

Sharper lens on frailty

Growing evidence shows humans age at different rates, shaped by genes, stress, exercise, and habits like smoking or drinking. While pricey genetic tests can reveal how DNA wears over time, FaceAge promises insight using only a selfie.

The model was trained on 58,851 portraits of presumed-healthy adults over 60, culled from public datasets.

It was then tested on 6,196 cancer patients treated in the United States and the Netherlands, using photos snapped just before radiotherapy. Patients with malignancies looked on average 4.79 years older biologically than their chronological age.

Among cancer patients, a higher FaceAge score strongly predicted worse survival -- even after accounting for actual age, sex, and tumor type -- and the hazard rose steeply for anyone whose biological reading tipped past 85.

Intriguingly, FaceAge appears to weigh the signs of aging differently than humans do. For example, being gray-haired or balding matters less than subtle changes in facial muscle tone.

FaceAge boosted doctors' accuracy, too. Eight physicians were asked to examine headshots of terminal cancer patients and guess who would die within six months. Their success rate barely beat chance; with FaceAge data in hand, predictions improved sharply.

The model even affirmed a favorite internet meme, estimating actor Paul Rudd's biological age as 43 in a photo taken when he was 50.

Bias and ethics guardrails

AI tools have faced scrutiny for under‑serving non-white people. Mak said preliminary checks revealed no significant racial bias in FaceAge's predictions, but the group is training a second‑generation model on 20,000 patients.

They're also probing how factors like makeup, cosmetic surgery or room lighting variations could fool the system.

Ethics debates loom large. An AI that can read biological age from a selfie could prove a boon for clinicians, but also tempting for life insurers or employers seeking to gauge risk.

"It is for sure something that needs attention, to assure that these technologies are used only in the benefit for the patient," said Hugo Aerts, the study's co-lead who directs MGB's AI in medicine program.

Another dilemma: What happens when the mirror talks back? Learning that your body is biologically older than you thought may spur healthy changes -- or sow anxiety.

The researchers are planning to open a public-facing FaceAge portal where people can upload their own pictures to enroll in a research study to further validate the algorithm. Commercial versions aimed at clinicians may follow, but only after more validation.